Valuation : Black Diamond Therapeutics, Inc.

Market Cap 117M 101M 95.1M 86.64M 163M 11.12B 164M 1.12B 438M 5.66B 440M 431M 18.76B P/E 2026 *
-3.31x
P/E 2027 * -2.14x
Enterprise Value 117M 101M 95.1M 86.64M 163M 11.12B 164M 1.12B 438M 5.66B 440M 431M 18.76B EV / Sales 2026 *
18.8x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day-2.86%
1 week-8.93%
Current month-2.86%
1 month+20.71%
3 months-9.73%
6 months-17.41%
Current year-16.05%
1 week 2.02
Extreme 2.02
2.32
1 month 1.68
Extreme 1.675
2.32
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
10.47
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 2023-09-15
Chief Tech/Sci/R&D Officer 51 2021-08-10
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 49 2018-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
3/20/26
NEA Management Co. LLC
OtherCompany 0 0% -
3/20/26 Free

Director

6,105 0.0107%
3/20/26 Free

Director

6,919 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
-2.86%-8.93%-25.82%-42.70% 121M
-0.25%-4.10%+38.38%+92.61% 68.13B
+1.21%+0.80%+46.29%+85.32% 63.6B
-0.25%-1.92%-10.72%+436.70% 26.6B
+0.33%-10.61%+1.95%-16.27% 25.52B
+1.18%-2.23%+30.87%-19.04% 19.69B
-6.09%-12.08%+226.11%+375.00% 18.23B
+1.22%-6.44%+0.78%+540.26% 15.16B
+4.12%+0.30%+52.03%+150.18% 13.54B
-0.24%+5.18%+23.04%+190.97% 12.48B
Average -0.43%-3.30%+38.29%+179.30% 26.31B
Weighted average by Cap. +0.01%-2.95%+42.02%+159.66%

Financials

2026 *2027 *
Net sales 6.25M 5.39M 5.07M 4.62M 8.69M 593M 8.74M 59.95M 23.34M 302M 23.47M 22.96M 1B -
Net income -36.96M -31.88M -29.99M -27.32M -51.38M -3.51B -51.66M -355M -138M -1.78B -139M -136M -5.92B -64.65M -55.77M -52.46M -47.79M -89.87M -6.14B -90.35M -620M -241M -3.12B -243M -237M -10.35B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
26-09-01 US$2.040 -2.86% 759,096
26-08-31 US$2.100 -5.83% 509,283
26-08-28 US$2.230 -1.76% 522,035
26-08-27 US$2.270 0.00% 458,907
26-08-26 US$2.270 +1.34% 491,288
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.040USD
Average target price
10.00USD
Spread / Average Target
+390.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock